COVID-19 Virus Not Retained in Placenta After Maternal Recovery

A new study from Yale University confirms that the SARS-CoV-2 virus does not persist in placental tissue after a pregnant woman recovers from COVID-19, offering reassurance about the safety of pregnancies following maternal infection.

The research, published in JAMA Network Open, examined placental tissue from women who had recovered from COVID-19 during pregnancy. Despite earlier concerns that the virus might linger in the placenta and potentially affect fetal development, the study found no evidence of SARS-CoV-2 RNA or viral proteins in placental samples collected weeks to months after maternal recovery.

While the virus itself clears from the placenta, the study acknowledged that COVID-19 infection during pregnancy can still leave behind structural and inflammatory changes in placental tissue. These changes, which may include perivillous fibrin deposition, monocytic intervillositis and trophoblast necrosis, have been associated with complications such as stillbirth in severe cases of placental infection, known as COVID-19 placentitis.

The findings build on prior observations linking severe maternal SARS-CoV-2 infection to adverse pregnancy outcomes, but clarify that ongoing viral presence is not a mechanism for harm after recovery. Researchers emphasized that while placental damage may occur during acute infection, it does not appear to be driven by persistent viral reservoirs in the tissue.

The study’s authors noted that further research is needed to understand the long-term implications of placental inflammation following COVID-19 in pregnancy, particularly in cases where infants may be born preterm or with low birth weight. However, the absence of persistent virus supports the conclusion that the placenta does not serve as a reservoir for SARS-CoV-2 after maternal recovery.